您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Sevelamer Carbonate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Sevelamer Carbonate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Sevelamer Carbonate图片
CAS NO:845273-93-0
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
Sevelamer carbonate 是一种具有口服活性的非钙基磷酸盐结合剂 (phosphate binding agent),用于慢性肾脏病 (CKD) 的高磷血症研究。Sevelamer carbonate 能有效降低体内血清磷水平,但对体内血清钙、氯水平影响极小。Sevelamer carbonate 被认为是七氟乙烯 (HY-13995) 的一种改进的缓冲形式。
生物活性

Sevelamer carbonate is an orally active and non-calcium-basedphosphate binding agentand used for the hyperphosphatemia of chronic kidney disease (CKD)research. Sevelamer carbonate effectively lowers serum phosphorus levels hile having minimal effect on serum calcium or serum chloride levels in vivo. Sevelamer carbonate is considered as an improved, buffered form of sevelamer (HY-13995)[1][2].

体外研究
(In Vitro)

Sevelamer carbonate (15 mg/mL; pH=6 or 8) decreases serum levels of gut-derived uremic toxins (such as IAA) or limits the elevation of gut-derived uremic toxins (initial concentration=1 μg/mL or 10 μg/mL)[5].

体内研究
(In Vivo)

Sevelamer carbonate is an anion-exchange resin with the same polymeric structure as that of sevelamer hydrochloride, but with carbonate replacing chloride as the anion[4].
Sevelamer carbonate lowers serum phosphorus levels and calcium-phosphorus product to a similar extent as sevelamer hydrochloride. Additionally, Sevelamer carbonate is associated with significant effects on decreasing low-density lipoprotein cholesterol levels and may cause less metabolic acidosis than sevelamer hydrochloride in vivo[1].
Sevelamer carbonate (oral adminstration; 1% mixed in diet; 2-3 weeks) significantly reduces serum phosphate level in Npt2b-deficient mice. Npt2b attenuates the hyperphosphatemia in control animals and that sevelamer carbonate treatment has an additional benefit in maintaining serum phosphate in the normal range[3].
Sevelamer carbonate (oral adminstration; 1% mixed in diet; 2-3 weeks) does not alter serum phosphate levels in uremic WT mice (10.04 mg/dl , untreated versus 9.67mg/dl , binder-treated mg/dl) but further decreased serum phosphate levels in uremic Npt2b–/– mice in uremic mouse model[3].

Animal Model:WT and Npt2b–/– CKD mice model[3]
Dosage:1% mixed in diet
Administration:Oral adminstration; 1% mixed in diet; 2-3 weeks
Result:Attenuated chronic hyperphosphatemia in mice.
Clinical Trial
Formula

(C3H7N.C3H5ClO)x.xH2CO3

CAS 号

845273-93-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.